Masahito Ohji
VIENNA — Ninety-six-week outcomes of the ALTAIR study demonstrated safety and efficacy of treat-and-extend aflibercept administration with both 2-week and 4-week adjustments in patients with wet AMD. The study involved 255 patients treated at 40 sites in Japan.
“Patients received three monthly doses of aflibercept and were then equally randomized in one of the two arms. In the first arm, the treatment interval was extended or shortened by 2 weeks. In the second arm, it was extended by 4 weeks or shortened by 2 or 4 weeks, depending (Read more...)
Uncategorized